The personnel adjustment and changes of multinational pharmaceutical companies are frequent, and the industry believes that this is the reason

[Pharmaceutical Network Market Analysis] In the past two years, multinational pharmaceutical companies have set off a new round of organizational restructuring, with frequent personnel changes
.

Since April this year, a number of multinational pharmaceutical companies have announced major personnel changes, involving presidents and vice presidents
.

Recently, three multinational pharmaceutical companies have announced major personnel appointments.
Recently, it is reported that following Novartis Global's announcement to integrate the two business divisions of pharmaceuticals and oncology into an innovative drug division, Novartis has confirmed the international regional heads of innovative drugs.
Among them, Novartis Zhang Ying, President of Pharma (China), was appointed President and Managing Director of Innovative Medicines China, effective June 1
.

It is understood that Zhang Ying has worked in many multinational pharmaceutical companies such as AstraZeneca and Pfizer.
Since joining Novartis, she has established the Novartis Specialty Drug Team and has been appointed as Novartis Pharmaceuticals COO, CPO, and President of China
.

During Zhang Ying's tenure, Novartis China achieved double-digit growth for five consecutive years, and promoted the launch of a number of innovative drugs in China
.

 　　Coincidentally, Boehringer Ingelheim also announced a major personnel appointment recently.
Guan Hongjuan, the current vice president of human resources for BI Greater China, has decided to retire from the company
.

At the same time, it was announced that from May 1, Xie Fang, the current HR business partner of BI Greater China Human and Pharmaceutical Business Unit, will take over the position of Vice President of Human Resources of BI Greater China, join the BI Greater China leadership team, and become BI Member of the Global Human Resources Committee, based in Shanghai, reporting directly to Gao Qifei, CEO and President of BI Greater China, and reporting to Sven Sommerlatte, Head of BI's Global Human Resources Department
.

 　　In addition, Bayer has appointed Dr.
Tara Frenkl to lead its Oncology Strategic Business Unit, effective April 25, reporting directly to Christine Roth
.

Both Tara Frenkl and Christine Roth were previously at GSK, with Frenkl previously serving as senior vice president and head of oncology drug development at GSK, while Roth was a senior GSK global oncologist before joining Bayer on March 1.
Vice President, currently head of the Oncology Strategy Business Unit at Bayer Pharma
.

 　　The domestic pharmaceutical industry has entered a new round of transition pain, and multinational pharmaceutical companies are affected Analysts believe that for multinational companies, the replacement of executives is actually mainly due to the domestic pharmaceutical industry entering a new round of transition pain
.

In recent years, a series of pharmaceutical reform policies released in China, such as the normalization of drug purchases in bulk, as well as the implementation of national medical insurance negotiation, consistency evaluation and other medical policies, are making more and more multinational pharmaceutical companies’ original drugs no longer available.
Enjoy "super-national treatment"; at the same time, it is also subjecting multinational pharmaceutical companies to more and more competitive pressure
.

Therefore, in order to cope with this situation, in recent years, these pharmaceutical companies have accelerated their domestic layout adjustments
.

 　　Since the beginning of this year, in addition to frequent changes in personnel, multinational pharmaceutical companies have also made frequent moves in business structure.
In addition, they are constantly selling assets and businesses.
.
.
For example, on April 1, Daiichi Sankyo (China) and Chongqing Yaoyou Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Chongqing Yaoyou") signed an equity transfer agreement
.

According to the agreement, Daiichi Sankyo (China) will transfer to Chongqing Yaoyou the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company that produces the preparations.
The transfer is expected to be completed by the end of August this year
.

 　　From the current point of view, a series of measures such as organizational structure adjustment, business line divestiture and merger, and executive replacement of multinational pharmaceutical companies have become the norm
.

The industry expects that under the background of shrinking profits of domestic generic drugs and vigorously promoting the development of innovative drugs, accelerating the adjustment of business and strategies in the Chinese market will become a normal operation for multinational pharmaceutical companies to maintain their competitive advantages, and the resulting personnel changes will also will become more frequent
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.